My watch list  


Systematic (IUPAC) name
CAS number 63659-18-7
ATC code C07AB05 S01ED02
PubChem 2369
DrugBank APRD00245
Chemical data
Formula C18H29NO3 
Mol. mass 307.428 g/mol
Pharmacokinetic data
Bioavailability 89%
Metabolism Hepatic
Half life 14-22hours
Excretion Renal (20%)
Therapeutic considerations
Pregnancy cat.


Legal status

Prescription only

Routes oral, ocular

Betaxolol (trade names Betoptic, Betoptic S, Lokren) is a selective beta1 receptor blocker used in the treatment of hypertension and glaucoma. Being selective for beta1 receptors, it typically has fewer systemic side effects than non-selective beta-blockers, for example, not causing bronchospasm (mediated by beta2 receptors) as timolol may. Betaxolol also shows greater affininty for beta1 receptors than metoprolol. In addition to its effect on the heart, betaxolol reduces the pressure within the eye (intraocular pressure). This effect is thought to be caused by reducing the production of the liquid (which is called the aqueous humor) within the eye. The precise mechanism of this effect is not known. The reduction in intraocular pressure reduces the risk of damage to the optic nerve and loss of vision in patients with elevated intraocular pressure due to glaucoma.

Betaxolol was approved by the U.S. Food and Drug Administration (FDA) for ocular use as a 0.5% solution (Betoptic) in 1985 and as a 0.25% solution (Betoptic S) in 1989.

See also


This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Betaxolol". A list of authors is available in Wikipedia.
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE